CCHT: GenSci134 injection domestic production drug registration clinical trial application approved
I'm PortAI, I can summarize articles.
CCHT's subsidiary, GenSci Pharmaceutical, has received approval from the National Medical Products Administration for the domestic production drug registration clinical trial application of GenSci134 injection. This drug is a biological product for the treatment of growth hormone deficiency, suitable for adult and pediatric patients, especially for those with idiopathic short stature
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments